<DOC>
	<DOC>NCT00723749</DOC>
	<brief_summary>The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life conditions.</brief_summary>
	<brief_title>Treatment of Opioid Dependent Patients With Suboxone: Acceptability &amp; Safety Data From Real Life Scenario (Study P05603)</brief_title>
	<detailed_description>Nonprobability sampling was done by invitation to volunteer with the intention to document 4 to 5 patients per physician where a substitution therapy with Suboxone is planned and indicated.</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Both adult and adolescent patients over 15 years of age who have consented to addiction treatment for opioid dependence within the scope of medical, social and psychotherapeutic measures can be included. Therapeutic indications and contraindications for SUBOXONE® must be observed when selecting patients. In accordance with the product information, it is to be taken into consideration that patients are not suffering simultaneously from acute alcoholism, delirium tremens, or severe respiratory and severe liver insufficiency.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Suboxone</keyword>
	<keyword>Subutex</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Naloxone</keyword>
</DOC>